Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Capital Expenditures (2016 - 2025)

Pediatrix Medical (MD) has disclosed Capital Expenditures for 17 consecutive years, with -$11.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 440.12% to -$11.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.5 million, a 93.32% decrease, with the full-year FY2025 number at $1.5 million, down 93.32% from a year prior.
  • Capital Expenditures was -$11.7 million for Q4 2025 at Pediatrix Medical, down from $5.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $10.5 million in Q3 2021 to a low of -$26.8 million in Q4 2021.
  • A 5-year average of $1.6 million and a median of $6.4 million in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 116.07% in 2024, then plummeted 440.12% in 2025.
  • Pediatrix Medical's Capital Expenditures stood at -$26.8 million in 2021, then soared by 32.56% to -$18.1 million in 2022, then dropped by 18.54% to -$21.4 million in 2023, then soared by 116.07% to $3.4 million in 2024, then tumbled by 440.12% to -$11.7 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Capital Expenditures are -$11.7 million (Q4 2025), $5.3 million (Q3 2025), and $4.5 million (Q2 2025).